Aytu BioPharma Buyout Sets $2.70 Per-Share Target for Investors
Rosemont’s agreement to acquire Aytu BioPharma at $2.70 per share gives small-cap healthcare investors a clear merger-arbitrage reference point.
DOJ Review Puts DoorDash’s Instacart Deal Under the Antitrust Microscope
A DOJ review adds regulatory uncertainty to DoorDash’s proposed Instacart acquisition, putting timing and merger-arbitra…
Carlisle’s PermaTherm Deal Expands Its Building-Products Footprint
Carlisle’s agreement to acquire PermaTherm adds insulated metal panels and related products to its building-envelope pla…
Anthropic Sets $70-$78 IPO Range for Nasdaq Debut Under ANT
Anthropic’s proposed $70-$78 IPO range will put AI investor appetite and high-growth valuations to a live test when ANT …
Informed positions start with informed mornings.
Market-moving analysis and institutional-grade research, complimentary and delivered daily.